小肠细菌过度生长 中国就医指南

Small Intestinal Bacterial Overgrowth (SIBO) is a chronic gastrointestinal disorder characterized by an excessive proliferation of bacteria—typically exceeding 10^5 colony-forming units per milliliter—in the proximal small intestine, where bacterial concentrations are normally low (<10^3 CFU/mL). Unlike colonic microbiota, these overgrown microbes interfere with nutrient digestion and absorption, ferment carbohydrates prematurely, and damage the intestinal mucosa. Pathogenesis involves multiple interrelated mechanisms: impaired intestinal motility (especially disrupted migrating motor complex activity), anatomical abnormalities (e.g., surgical blind loops, strictures, diverticula), reduced gastric acid secretion (hypochlorhydria), immune dysfunction, and altered gut barrier integrity. These disruptions create a permissive environment for bacterial colonization and dysbiosis. Epidemiologically, SIBO prevalence is estimated at 4–15% in the general population but rises sharply in specific cohorts: up to 60–70% in patients with irritable bowel syndrome (IBS), 30–50% in those with systemic sclerosis or diabetes-related gastroparesis, and 25–40% among older adults with functional GI disorders. Risk factors include long-term proton pump inhibitor (PPI) use, chronic opioid therapy, prior gastric bypass or bariatric surgery, pancreatic exocrine insufficiency, celiac disease (especially refractory cases), and connective tissue diseases affecting gut motility. SIBO significantly impairs quality of life: patients commonly report debilitating bloating, abdominal distension, crampy pain, diarrhea or constipation (or alternating patterns), fatigue, brain fog, and unintentional weight loss. Nutritional deficiencies—including iron, vitamin B12, fat-soluble vitamins (A, D, E, K), and folate—are frequent due to malabsorption and bacterial consumption of nutrients. Psychosocial impact is substantial: chronic symptoms correlate with increased anxiety, depression, work absenteeism, and reduced social engagement. Diagnosis remains challenging and relies on clinical suspicion combined with breath testing (glucose or lactulose hydrogen/methane), though limitations in sensitivity and specificity necessitate careful interpretation. Emerging evidence also links SIBO to systemic inflammation and metabolic disturbances, underscoring its relevance beyond symptomatic management. Early recognition and multidisciplinary intervention—including gastroenterology, nutrition support, and motility specialists—are essential to mitigate complications such as osteoporosis, anemia, and progressive intestinal damage.

# 小肠细菌过度生长（SIBO）治疗方案与费用明细（消化内科）

一、非手术/保守治疗方案

适用人群：初发、轻中度症状（腹胀、腹泻、营养不良）、无结构性肠病者。

• •诊断检查费：氢/甲烷呼气试验（300–500元）、小肠液培养（1200–1800元）、血清维生素B₁₂/叶酸/脂肪酶检测（400–600元）
• •药物治疗（疗程2–4周）：

- 替代方案（新霉素+甲硝唑联合）：800–1500元/疗程

• •饮食干预+微生态调节：低FODMAP饮食指导（200–400元/次）、益生菌（布拉氏酵母菌/特定乳杆菌复合制剂）：300–900元/月

二、手术/介入方案

注：SIBO本身指征；仅针对继发性病因（如术后盲袢、肠粘连、肠瘘）行微创探查或重建术。

• •适应证：明确解剖异常（如吻合口狭窄、憩室、肠瘘）经内镜/影像证实者
• •术前检查：小肠CTE/MRE（1200–2000元）、胃肠动力检测（800–1500元）
• •腹腔镜探查+粘连松解/总费用28,000–45,000元（含住院、麻醉、耗材）

三、复杂/耐药/并发症方案

• •反复复发（≥3次）：延长利福昔明脉冲疗法（每月5天×3月）：3500–6000元；加用熊去氧胆酸（改善胆汁酸代谢）：600–1200元/月
• •严重营养不良/维生素缺乏：静脉补充维生素B₁₂（300–500元/次，需4–6次）、肠内营养支持（安素等）：2000–4000元/月

四、方案快速选择指南

• •预算≤3000元/年：首选呼气试验+利福昔明单疗程+低FODMAP饮食
• •反复复发/合并糖尿病/硬皮病：推荐延长脉冲疗法+胃肠动力评估（总预算8000–12,000元/年）
• •存在明确解剖异常：转外科评估腹腔镜干预，避免长期抗生素依赖